Alliance to Develop Small Molecule Therapeutics
By Biotechdaily staff writers
Posted on 03 Jul 2002
A multiyear research collaboration to discover and develop small molecules for up to three therapeutic targets has been announced by Cephalon, Inc. (West Chester, PA, USA) and TransTech Pharma, Inc. (High Point, NC, USA).Posted on 03 Jul 2002
Under the agreement, Cephalon has the exclusive right to develop and commercialize all compounds directed at each of the targets covered by the collaboration. TransTech would receive payments upon the achievement of specified research and clinical and commercial milestones. Cephalon focuses on products to treat sleep and neurologic disorders, cancer, and pain. TransTech's high throughput drug discovery platform translates genomic and proteomic information into small molecules as therapeutics.
"The collaboration with TransTech is another step in maximizing the potential of our drug discovery efforts by utilizing TransTech's technology to enhance and diversify Cephalon's pipeline of potential therapeutics,” said Jeffrey L. Vaught, Ph.D., senior vice president of Cephalon.
Related Links:
Cephalon
TransTech
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Automated Urinalysis Solution
UN-9000
